К содержанию
РецензированоEN2026

COMPARISON OF SIDERAL® AND STANDARD ORAL IRON THERAPIES IN CHILDREN WITH CHRONIC KIDNEY DISEASE: EFFICACY AND TOLERABILITY STUDY

Ашурова Ноила Шухратовна · Мурадова Эмма Владимировна (PhD, ассистент кафедры Терапевтических предметов Университета Зармед · ) · ОRCID ID --- (Самаркандский Государственный Медицинский Университет) · Ганжиян Наринэ Эмильевна (Самаркандский Государственный Медицинский Университет)

Современная наука и исследования · 2 · 2026

Аннотация

The study compares SiderAL® (Sucrosomial® Iron) and traditional ferrous sulfate in treating anemia in children with chronic kidney disease (CKD). Sixty children aged 5– 15 years with CKD stages II–IV and iron deficiency anemia participated in a 12-week randomized study. Results showed that both therapies improved hemoglobin and serum iron levels, but SiderAL® produced significantly better results and fewer gastrointestinal side effects (6.7% vs. 26.7%). Treatment adherence was also higher with SiderAL® (93.3%). Thus, SiderAL® proved to be more effective and better tolerated than standard iron preparations for managing anemia in children with CKD. Keywords: Children, Chronic Kidney Disease, Anemia, Iron Deficiency, Sideral®, Sucrosomial® Iron. Background. Anemia is one of the most common and clinically significant complications of chronic kidney disease (CKD) in children, leading to impaired physical and cognitive development and a decreased quality of life [1,2]. The main etiological factor of anemia in CKD is iron deficiency, which may develop due to both absolute and functional depletion of iron stores [3,4]. However, the effectiveness of traditional oral iron preparations is often limited by their low bioavailability and the high incidence of gastrointestinal side effects [5,6]. Objective. To compare the efficacy and tolerability of SiderAL® (Sucrosomial® Iron) and traditional oral iron preparations in children with CKD and anemia. Materials and Methods. A prospective, randomized, open-label, comparative study was conducted in 60 children with stage II-IV CKD and laboratory-confirmed iron deficiency anemia. Patients were divided into two equal groups: − Group I (n=30): received ferrous sulfate; – Group II (n=30): received SiderAL®. The duration of therapy was 12 weeks. The following parameters were evaluated: hemoglobin (Hb), serum iron (Fe), total iron-binding capacity (TIBC), transferrin saturation (TSAT), frequency of adverse events, and treatment adherence (compliance). 716 ResearchBib IF - 11.01, ISSN: 3030-3753, Volume 2 Issue 10 Results. After therapy, both groups demonstrated a statistically significant increase in serum iron and hemoglobin levels (p < 0.001). The increase in Hb was more pronounced in the SiderAL® group (+30.8 g/L) compared to the ferrous sulfate group (+14.0 g/L, p < 0.001). The frequency of gastrointestinal adverse effects was notably lower in patients receiving SiderAL® (6.7%) compared to those receiving ferrous sulfate (26.7%).

Доказательный фрагмент

«The study compares SiderAL® (Sucrosomial® Iron) and traditional ferrous sulfate in treating anemia in children with chronic kidney disease (CKD).»

Образец извлечения

Демо-превью

The study compares SiderAL® (Sucrosomial® Iron) and traditional ferrous sulfate in treating anemia in children with chronic kidney disease (CKD). Полный текст публикации CiteX не хранит — доступ к первоисточнику открывается по DOI согласно лицензии издателя и выбранному плану.

Цитирований
0
Тип
Журнал
Страна
Узбекистан
Ключевые слова
Children, Chronic Kidney Disease, Anemia, Iron Deficiency, Sideral®, Sucrosomial® Iron.
Открыть DOI
Спросить CiteX об этой работе

Смежные источники